Comorbidities among Adults with Hemophilia: Hemophilia Utilization Group Studies (HUGS V)
A Comparison of US Prophylaxis Rates Shows Lower Prescribing for Severe Hemophilia B Patients than Severe Hemophilia A Patients
Addressing patient concerns about product switching in hemophilia A: Evaluating turoctocog alfa data from the guardian™ clinical trial program
Ongoing Prospective ADVATE Immune Tolerance Induction Registry (PAIR) Continues to Demonstrate Success Rates Consistent with Published Literature
The use of combination therapy with plasma derived and recombinant factor VIII in patients with hemophilia A: a single institution experience
Safety and Effectiveness of Anti Inhibitor Coagulation Complex (AICC) in Routine Clinical Management: a Post-Authorization Safety Study (PASS)
Safety of BAX 855, a Polyethylene Glycol (PEG) Conjugated Full-Length Recombinant Factor VIII Product
Extended-interval Dosing with rFIXFc Is Associated With Low Bleeding Rates and a Reduction in Weekly Factor Use
Dosing Routines and Bleeding Rates Before and Following Treatment with rFVIIIFc in the A-LONG Clinical Study
3-Year Results From SPINART: Prolonged Reduction of Bleeding With Prophylaxis Using Bayer’s Sucrose-Formulated Recombinant Factor VIII
SPINART Trial 3-Year Results With Bayer’s Sucrose-Formulated Recombinant Factor VIII: Improved Joint Function and Health-Related Quality of Life in Adults Using Prophylaxis
Dosing Flexibility in Prophylaxis Regimens With Bayer’s Sucrose-Formulated Recombinant Factor VIII: Experience From Postmarketing Surveillance Studies
Retrospective Database Analysis of the Prevalence of Cardiovascular Comorbidities in a US Patient Population with Hemophilia A: Confirmation of Findings
Real-world Dosing Patterns of Factor in Hemophilia B Patients
Real-world dosing of factor in hemophilia A patients
Identification of Previously Unreported F8 and F9 Gene Mutations in Hemophilia Subjects From the Phase 3 Clinical Trials of rFVIIIFc and rFIXFc
Safety and efficacy of a recombinant factor IX (BAX326*) in pediatric previously-treated patients with hemophilia B
Kids A-LONG: Safety, Efficacy, and Pharmacokinetics of Long-Acting Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Children with Hemophilia A
FEIBA PROOF: A Prospective, open-label, randomized, parallel study with FEIBA NF to evaluate the efficacy and safety of prophylactic versus on-demand treatment in haemophilia A or B subjects with inhibitors
The PROLONG-ATE Study: A Phase 2/3 Study to Evaluate Efficacy and Safety of BAX 855,A Longer-Acting PEGylated Full-Length Recombinant Factor VIII (PEG-rFVIII),for Prophylaxis and Treatment of Bleeding in Severe Haemophilia A
A Phase I Study of Safety and Pharmacokinetics of BAX 855, a Longer Acting PEGylated Full-Length Recombinant Factor VIII (PEG-rFVIII), in Patients with Severe Hemophilia A
Prevalence and Predictors of Food Insecurity in Children with Hemophilia
B-LONG: Phase 3 Study of Long-Lasting Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Hemophilia B
A-LONG: Phase 3 Study of Long-Lasting Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Hemophilia A
H. Pylori as a cause of iron deficiency in children with bleeding disorders
Objective:
Describe the role of H. pylori as a cause of chronic iron deficiency in children with congenital bleeding disorders.
Methods:
As part of their routine comprehensive care children at our haemophilia treatment center have a CBC done. Over the past year 4 children who underwent diagnostic workup for microcytic anemia were found to have iron deficiency associated with H. pylori infection. We describe the clinical findings in these children and their outcomes after appropriate therapy.
Summary:
From March 2012 to March 2013, 4 children were identified with iron deficiency anemia due to H. pylori. None of the 4 patients gave a history of excessive blood loss and none had GI symptoms such as weight loss, abdominal pain, vomiting or diarrhea. Clinical and laboratory findings at presentation are summarized below. No patients had thrombocytopenia.

Only one patient had positive occult blood in stool (RG) and underwent endoscopy. Diagnosis of H. pylori was made on gastric biopsy. RG also had 4 weeks of IV iron sucrose therapy. All patients were seen by gastroenterology and successfully treated with triple therapy consisting of amoxicillin, Biaxin, and omeprazole. RG had a recurrence and was retreated with quadruple therapy consisting of amoxicillin, metronidazole, omeprazole, and bismuth subsalicylate. All 3 patients with FVIII deficiency were also on secondary prohylaxis.
Conclusions:
H. pylori is a common cause of gastritis and often presents with upper gastrointestinal symptoms. It is also associated with idiopathic thrombocytopenic purpura. However, in children with congenital bleeding disorders, it may present with few symptoms and an incidental finding of iron deficiency anemia. We suggest that children with bleeding disorders should be screened for H. pylori as a cause of iron deficiency.